Novo Nordisk A/S with ticker code (NVO) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 131.79 and 117.5 with a mean TP of 125.53. Given that the stocks previous close was at 110.02 this would imply there is a potential upside of 14.1%. The day 50 moving average is 109.67 and the 200 day MA is 108.22. The market capitalisation for the company is $251,909m. Find out more information at: https://www.novonordisk.com
The potential market cap would be $287,422m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
